Phase I study of autologous CD8+and CD4+transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal and non-small cell lung cancers with KRAS G12V mutations

被引：0
|
作者：
Chiorean, Elena Gabriela
Coveler, Andrew
Safyan, Rachael
Cohen, Stacey
Lee, Sylvia
Yeung, Cecilia
Redman, Mary
Schmitt, Thomas
Chapuis, Aude
Greenberg, Philip D.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT082
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Phase I study of autologous CD8+and CD4+transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations.
    Safyan, Rachael A.
    Redman, Mary Weber
    Coveler, Andrew L.
    Cohen, Stacey A.
    Lee, Sylvia
    Yeung, Cecilia
    Schmitt, Thomas
    Chapuis, Aude
    Greenberg, Philip D.
    Chiorean, E. Gabriela
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS792 - TPS792
  • [2] Generating optimal-affinity T cell receptors targeting the shared neoantigen KRAS G12V using the humanized TCR transgenic mouse platform HuTCR.
    Leliavski, Alexei
    Knackstedt, Lorenz
    Oduro, Jennifer
    Selck, Claudia
    Dhamodaran, Arunraj
    Blankenstein, Thomas
    Kieback, Elisa
    Poncette, Lucia
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers
    Till, Jacob Edward
    Bucheit, Leslie A.
    Zhang, Nicole
    Clemens, Keelia M.
    Carpenter, Erica L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Mutant KRAS-specific T cell receptors directed against prevalent G12D and G12V variants exhibit potent cytotoxic activity and CD8 co-receptor independence
    Bear, Adham S.
    Nadler, Rebecca B.
    Scholler, John
    Vonderheide, Robert H.
    Linette, Gerald P.
    Carreno, Beatriz M.
    CANCER RESEARCH, 2022, 82 (22)
  • [5] RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non- small cell lung cancer (NSCLC)
    Reuss, Joshua E.
    Gandhi, Sunil G.
    Spigel, David R.
    Janne, Pasi A.
    Paz-Ares, Luis G.
    Gadgeel, Shirish M.
    Patel, Jyoti D.
    Passiglia, Francesco
    Spira, Alexander I.
    Edelman, Martin Joseph
    Blumenschein, George R.
    Shergill, Ardaman
    Burns, Timothy F.
    Bhambhani, Vijeta
    Patrick, Gloria
    Pachter, Jonathan A.
    Denis, Louis J.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] KRAS G12V T CELL RECEPTOR-ENGINEERED T CELLS EXPRESSING THE DURABILITY FAS-41BB SWITCH RECEPTOR EXHIBIT A POTENT, PERSISTENT, COORDINATED CD4/CD8 ANTI-TUMOR RESPONSE IN VITRO AND IN VIVO
    He, Xingyue
    Hoffmann, Michelle
    Liang, Jinsheng
    Qu, Hongjing
    Drain, Allison
    Lam, Hubert
    Oda, Shannon
    Schmitt, Thomas
    Chapuis, Aude
    Greenberg, Philip
    Shapiro, Gary
    Vincent, Loic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A360 - A360
  • [7] Attamage-A1: Phase I/II study of autologous CD8+and CD4+transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer.
    Schweizer, Michael Thomas
    Gooley, Ted
    Lee, Sylvia
    Gwin, William R.
    Dherin, Monica
    Hickner, Megan
    Casserd, Jennifer
    McAfee, Megan
    Schmitt, Thomas
    Yeung, Cecilia C. S.
    Gadi, Vijayakrishna K.
    Chapuis, Aude
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] AFNT-211: A phase1 study of autologous CD4+and CD8+T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Mitchell, Shaunica
    Khan, Binaish
    Payumo, Francis
    Chiorean, E. Gabriela
    Gahvari, Zhubin
    Hecht, J. Randolph
    Hurwitz, Michael
    Leidner, Rom
    Lenz, Heinz-Josef
    Pelster, Meredith
    Punekar, Salman
    Schoenfeld, Adam
    Zhao, Dan
    Vallaster, Markus
    Nagorsen, Dirk
    CANCER RESEARCH, 2024, 84 (07)
  • [9] AFNT-211: A phase 1 study of autologous CD4+and CD8+T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Mitchell, Shaunica
    Khan, Binaish
    Payumo, Francis
    Chiorean, E. Gabriela
    Gahvari, Zhubin
    Hecht, J. Randolph
    Hurwitz, Michael E.
    Leidner, Rom
    Lenz, Heinz-Josef
    Pelster, Meredith
    Punekar, Salman Rafi
    Schoenfeld, Adam Jacob
    Zhao, Dan
    Vallaster, Markus P.
    Nagorsen, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] ATTAC-MCC: Phase I/II study of autologous CD8+and CD4+transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade.
    Veatch, Joshua
    Akkiraju, Ananth
    Darwanto, Agus
    Garrity, Sean
    Hallet, Damien
    Nguyen, Kim
    Pierog, Piotr
    Sewastianik, Tomasz
    Vallaster, Markus P.
    Vincent, Loic
    Chapuis, Aude
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1